AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy
LONDON, April 15, 2008--AstraZeneca today announced it has entered into a settlement agreement in its Nexium patent infringement litigation against Ranbaxy Laboratories Ltd. and its affiliates (“Ranbaxy”).
The agreement settles the patent infringement litigation filed
by AstraZeneca following Ranbaxy’s submission to the United
States Food & Drug Administration of an Abbreviated New Drug
Application for a generic version of Nexium. Under the settlement
agreement, Ranbaxy concedes that all six patents asserted by
AstraZeneca in the patent litigation are valid and enforceable.
Ranbaxy also accepts that four of the patents would be infringed by
the unlicensed sale of Ranbaxy’s proposed generic
Manufacturing and Distribution
15 April 2008
|Notes To Editors|
Nexium belongs to a class of medicines known as proton-pump inhibitors (PPIs). It works by binding to, and inhibiting, the acid pumps of a particular type of cell which is found in the stomach. In doing so, it lowers the level of acidity in the stomach and helps to heal erosions in the esophagus or ulcers in the duodenum.
Nexium is an effective treatment for patients with gastroesophageal reflux disease (GERD), but is particularly appropriate for those suffering from persistent, recurrent GERD which can cause disruptive, long term symptoms. Nexium has been demonstrated to provide enduring relief from the impact of GERD amongst patients.
Nexium was first launched in Europe in 2000 and in 2001 in the US.
Plendil (felodipine) is a calcium antagonist for the treatment of hypertension and angina.
Prilosec (omeprazole), marketed as Losec in some countries, was the first PPI and is used for the short-term treatment of acid-related diseases.
AstraZeneca is a major international healthcare business engaged in research, development, manufacturing and marketing of prescription pharmaceuticals and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection product sales. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.
Broadcast quality footage is available to download from the Media section of our website at: http://br.thenewsmarket.com/Astrazeneca/br/Login/LoginPreRegistration.aspx
Journalists will be required to register to access this feature.
Posted: April 2008